NOVA.F - Novo Nordisk A/S

Frankfurt - Frankfurt Delayed Price. Currency in EUR
57.50
0.00 (0.00%)
At close: 3:32PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close57.50
Open58.00
Bid57.50 x 100000
Ask58.50 x 100000
Day's Range57.50 - 58.00
52 Week Range42.20 - 61.00
Volume100
Avg. Volume150
Market Cap135.531B
Beta (5Y Monthly)0.41
PE Ratio (TTM)23.35
EPS (TTM)2.46
Earnings DateN/A
Forward Dividend & Yield1.45 (2.52%)
Ex-Dividend DateMar 27, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GuruFocus.com

      Biomarin's Hemophilia A Drug Among 5 Up for FDA Approval Soon

      If approved, company’s Roctavian would become first gene therapy for inherited disease Continue reading...

    • 5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus Storm
      GuruFocus.com

      5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus Storm

      Stocks to consider as biotech company Novavax gets $1.6 billion in federal aid for Covie-19 vaccine Continue reading...

    • Abbott Deal, UnitedHealth Coverage Push Up Tandem Shares
      GuruFocus.com

      Abbott Deal, UnitedHealth Coverage Push Up Tandem Shares

      Stock of San Diego-based medical device company hits one-year high Continue reading...

    • Barrons.com

      12 European Stocks for the Second Half of 2020

      Bet on health care, utilities, technology, and staples headed into what could be an uncertain second half, says J.P. Morgan.

    • Novo Nordisk Completes Two Studies on Obesity Candidate
      Zacks

      Novo Nordisk Completes Two Studies on Obesity Candidate

      Novo Nordisk (NVO) provides data from a monotherapy study and a combination study on AM833.

    • Is Novo Nordisk (NVO) a Smart Long-term Buy?
      Insider Monkey

      Is Novo Nordisk (NVO) a Smart Long-term Buy?

      Saturna Capital Corporation is the investment management company of Sextant Mutual Funds. Sextant Mutual Funds recently released Q1 2020 Investor Letter, a copy of which you can download here. The Sextant Growth Fund posted a return of -15.13% for the quarter, outperforming its benchmark, the S&P 500 Index which returned -19.60% in the same quarter. […]

    • Before You Buy Novo Nordisk (NVO) Stock, Read This
      Insider Monkey

      Before You Buy Novo Nordisk (NVO) Stock, Read This

      Amana Mutual Funds Trust recently released its Q1 2020 Investor Letter, a copy of which you can download here. The Amana Income Fund posted a return of -18.01% for the quarter, outperforming its benchmark, the S&P 500 Index which returned -19.60% in the same quarter. You should check out Amana Mutual Fund's top 5 stock […]

    • Here is What Hedge Funds Think About Novo Nordisk A/S (NVO)
      Insider Monkey

      Here is What Hedge Funds Think About Novo Nordisk A/S (NVO)

      The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

    • Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals
      Zacks

      Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals

      J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.

    • The Daily Biotech Pulse: FDA Nod For Viela, 3 IPOs And Hematology Congress Presentations
      Benzinga

      The Daily Biotech Pulse: FDA Nod For Viela, 3 IPOs And Hematology Congress Presentations

      Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 11) * ADC Therapeutics SA (NYSE: ADCT) * Applied Molecular Transport Inc (NASDAQ: AMTI) (IPOed June 5) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Novo Nordisk A/S (NYSE: NVO)(announced a deal to buy privately held Corvidia Therapeutics that is developing therapies for cardio-renal diseases for up to $2.1 billion) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN)(announced commencement of first human trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19) * Sarepta Therapeutics Inc (NASDAQ: SRPT) * Zynex Inc. (NASDAQ: ZYXI) (announced addition to the S&P SmallCap 600 Index)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 11) * Ayala Pharmaceuticals Inc (NASDAQ: AYLA) * CALLIDITAS THER/S ADR (NASDAQ: CALT)(IPOed June 5) * Evofem Biosciences Inc (NASDAQ: EVFM) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Vaccinex Inc (NASDAQ: VCNX)Stocks In Focus Leap Therapeutics's Cancer Drug Gets Orphan Drug Designation Leap Therapeutics Inc (NASDAQ: LPTX) said the FDA U.S. Food and granted orphan drug designation for its DKN-01 for the treatment of gastric and gastroesophageal junction cancer. The company said DKN-01 is currently being evaluated in Phase 1/2 and Phase 2 clinical trials for gastroesophageal, gynecologic, hepatobiliary, and prostate cancers.The stock climbed 28.44% to $2.40 in after-hours trading.Virtual European Hematology Association Congress Presentations Agios Pharmaceuticals Inc (NASDAQ: AGIO) reported interim data from its ongoing Phase 2 study evaluating single agent mitapivat in non-transfusion-dependent α\- and β-thalassemia, which showed it induced hemoglobin increase of 1 g/dl or more in 12 of 13 evaluable patients, including 4 of 4 α-thalassemia patients during Weeks 4-12. The company said 7 of the 8 evaluable patients achieved sustained hemoglobin response during Weeks 12-24.The company noted that one Grade 3 adverse events of renal dysfunction was reported related to the treatment post cut-off date but was resolved upon treatment discontinuation.The stock was sliding 9.79% to $45.71 in pre-market trading.Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) presented at the EHA meeting new clinical data for CTX001, an investigational CRISPR/Cas9 gene-editing therapy, from the CLIMB-111 and CLIMB-121 Phase 1/2 trials in transfusion-dependent beta thalassemia, or TDT, and severe sickle cell disease, or SCD.Long-term follow-up data from a TDT patient showed at 15 months after CTX001 infusion, the patient was transfusion independent and had appreciable hemoglobin levels. The second patient was transfusion independent at five months.New data from one SCD patient showed nine months after CTX001 infusion, the patient was free of vaso-occlusive crises, was transfusion independent and had an increase in hemoglobin levels.Vertex shares were edging up 0.42% to $265 and Crispr was advancing 2.18% to $61 in pre-market trading.Editas Medicine Inc (NASDAQ: EDIT) announced results from a pre-clinical, proof-of-concept study of EDIT-301 in SCD, with both in-vitro and in-vivo studies revealing several desirable properties.The stock was rising 4.40% to $26.11 in pre-market trading.Viela Receives FDA Approval For Neurological Autoimmune Disorder Drug Viela Bio Inc (NASDAQ: VIE) said the FDA approved its Uplizna for the treatment of adult patients with neuromyelitis optica spectrum disorder, or NMOSD, who are anti-AQP4 antibody positive as a twice-a-year maintenance regimen following initial doses. Approximately 80% of all patients with NMOSD test positive for anti-AQP4 antibodies. The company is expects to launch the drug commercially in June.In pre-market trading, the stock was gaining 6.55% to $54.82.Quidel Gets $635,000 BARDA Funding For 4-Virus Point-Of-Care Test Quidel Corporation (NASDAQ: QDEL) said it has received funding from the Biomedical Advanced Research and Development Authority, or BARDA, to support the development of a point-of-care diagnostic assay that potentially tests for four respiratory viruses: SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus. The respiratory virus panel would be developed to run on Quidel's Sofia 2 flagship instrument.The company said funding began May 29, 2020, and will run through April 2021, totaling approximately $635,000. The goal of the funding, according to the company, is to achieve an Emergency Use Authorization for the test within the funding period.FDA Approves Mylan-Biocon's Diabetes Drug Mylan NV (NASDAQ: MYL) along with its Indian partner Biocon said the FDA approved their Semglee - insulin glargine injection - in vial and pre-filled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. Semglee has an identical amino acid sequence to Sanofi SA's (NASDAQ: SNY) Lantus and is approved for the same indications.Mylan shares were adding 3.37% to $16.85 in pre-market trading.On The Radar Clinical Readouts/Presentations Principia Biopharma is due to present at the American Academy of Dermatology Virtual Meeting Experience, full data set presentation from the Phase 2 Part B pemphigus trial with its investigational drug rilzabrutinib.Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) will present at the American Diabetes Association 80th Scientific Sessions posters on oral insulin ORMD-0801's effects on glucose parameters in uncontrolled Type 2 diabetes, oral insulin-induced reduction in liver fat content in Type 2 diabetic patients with non-alcoholic steatohepatitis and evening oral insulin glycemic effects in uncontrolled Type 2 diabetes patientsIPO Vaxcyte, Inc., a company developing vaccines to prevent or treat the most common and deadly infectious diseases, priced its upsized initial public offering, or IPO, of 15.625 million shares of its common stock at $16 per share. The shares will begin trading on the Nasdaq under the ticker symbol PCVX.La Jolla, California-based Avidity Biosciences, Inc. priced its upsized IPO of 14.4 million shares at $18 per share compared to the estimated price range of $17-$18. The shares of the biopharma, which develops a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates to treat a wide range of serious diseases, will be listed on the Nasdaq under the ticker symbol RNA.Cambridge, Massachusetts-based gene therapy company Generation Bio Co priced its IPO of 10.53 million shares at $19 per share compared to the estimated price range of $18-$19. The company's shares will begin trading on the Nasdaq under the ticker symbol GBIO.See more from Benzinga * The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO * The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset * The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash
      Zacks

      Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash

      Novo Nordisk (NVO) enters into a deal to acquire Corvidia Therapeutics for an upfront payment of $725 million in cash.

    • Novo Nordisk expands into cardiovascular disease with $725 million deal
      Reuters

      Novo Nordisk expands into cardiovascular disease with $725 million deal

      Novo Nordisk has agreed to buy AstraZeneca spin-off Corvidia Therapeutics for an initial $725 million as the world's largest diabetes drugmaker seeks to expand into cardiovascular disease treatments. The acquisition is in line with Novo's strategy to diversify its portfolio and gain a foothold in markets for drugs closely linked to its core therapeutic areas of diabetes and obesity. "Novo Nordisk has in recent years formulated a clearer strategy in cardiovascular diseases," Novo's chief science officer Mads Krogsgaard Thomsen said in an interview.

    • The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global
      Zacks

      The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global

      The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global

    • Top Stock Reports for Novo Nordisk, IBM & Honeywell
      Zacks

      Top Stock Reports for Novo Nordisk, IBM & Honeywell

      Top Stock Reports for Novo Nordisk, IBM & Honeywell

    • White House announces plan for Medicare enrollees to get insulin for $35 a month
      MarketWatch

      White House announces plan for Medicare enrollees to get insulin for $35 a month

      Medicare recipients will be able to get prescription plans that limit copays for insulin, a potential savings of hundreds of dollars, the White House announced Tuesday in a pivot to pocketbook issues that could influence November’s election.

    • Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY
      Zacks

      Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY

      Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.

    • Novo Nordisk A/S (CPH:NOVO B) Just Beat Earnings: Here's What Analysts Think Will Happen Next
      Simply Wall St.

      Novo Nordisk A/S (CPH:NOVO B) Just Beat Earnings: Here's What Analysts Think Will Happen Next

      A week ago, Novo Nordisk A/S (CPH:NOVO B) came out with a strong set of quarterly numbers that could potentially lead...

    • Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
      Zacks

      Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

      Novo Nordisk (NVO) beats on Q1 sales and earnings, and maintains outlook amid the coronavirus pandemic.

    • Novo Nordisk A/S (NVO) Q1 2020 Earnings Call Transcript
      Motley Fool

      Novo Nordisk A/S (NVO) Q1 2020 Earnings Call Transcript

      Image source: The Motley Fool. Novo Nordisk A/S (NYSE: NVO)Q1 2020 Earnings CallMay 6, 2020, 7:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorHello and welcome to the Q1 2020 Novo Nordisk AS Earnings Conference Call.

    • Reuters

      European shares flat as mixed earnings, U.S.-China tensions weigh

      European shares opened little changed on Wednesday as a batch of mixed earnings reports and simmering U.S.-China tensions added to doubts about a swift economic recovery even as many countries eased lockdown measures. The pan-European STOXX 600 index was flat as losses in oil and gas sector, following a recent surge, offset gains in healthcare shares. The global mood also remained fragile as U.S. President Donald Trump again took aim at China, urging it to be transparent about the origins of the novel coronavirus outbreak.

    • Novo Nordisk (CPH:NOVO B) Could Easily Take On More Debt
      Simply Wall St.

      Novo Nordisk (CPH:NOVO B) Could Easily Take On More Debt

      Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

    • 5 Pharmaceutical Companies to Consider as Coronavirus Vaccine Race Heats Up
      GuruFocus.com

      5 Pharmaceutical Companies to Consider as Coronavirus Vaccine Race Heats Up

      Biotech and drug manufacturing companies with the strength to weather further coronavirus storms Continue reading...

    • Novo Nordisk offers free 90-day insulin supply to people experiencing financial hardship due to COVID-19
      PR Newswire

      Novo Nordisk offers free 90-day insulin supply to people experiencing financial hardship due to COVID-19

      People with diabetes using Novo Nordisk Inc. insulin who have lost health insurance coverage because of a change in job status due to the COVID-19 pandemic may now be eligible for enrollment in our Diabetes Patient Assistance Program (PAP) and receive insulin free of charge for 90 days.

    • Reuters

      Europe's coronavirus export bans raise concern over insulin supplies

      Several European countries have banned the export of insulin in recent weeks, a move industry officials said was based on a misguided fear that the COVID-19 pandemic would cause shortages of a drug vital to millions of diabetes patients. EU curbs on drug exports during the coronavirus emergency mostly cover medication used to treat COVID-19, including muscle relaxants, painkillers and hydroxychloroquine.

    • Reuters

      Eli Lilly lowers insulin costs as coronavirus crisis deepens

      Drugmaker Eli Lilly & Co said on Tuesday it has capped the out-of-pocket cost for insulin to $35 per month to help diabetes patients across the United States, many of whom are facing financial difficulties due to the coronavirus outbreak. The new co-pay scheme covers most of Lilly's insulins, including widely-used Humalog injection, and can be availed by people with commercial insurance as well as those without insurance. "Enabling a $35-per-month insulin co-pay regardless of employment status will help many Americans in this difficult time," said CEOs Aaron Kowalski and Thom Scher of non-profit organization JDRF-Beyond Type 1 Alliance.